BioSpace News Archive

Clinical trial activities have traditionally centered around trial sites where patients travel for participation. This approach can place a time or cost burden on patients, creating an inconvenience that can limit enrollment speed or trial completion. To transcend these limitations, clinical researchers are continually identifying ways to leverage emerging mobile technologies and increased connectivity within decentralized cl

Lumen Bioscience , a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the closing of a $16 million Series B financing. The financing was co-led by new investor WestRiver Management and returning investor Bioeconomy Capital, with additional

Promega today launched its benchtop capillary electrophoresis (CE) instrument, the Spectrum Compact CE System, developed in collaboration with Hitachi High-Tech. The personal CE system is an integrated DNA analysis instrument that enables life scientists in laboratories of all sizes to perform Sanger sequencing and fragment

80% reduction in relative risk of invasive mechanical ventilation and/or death in patients treated with lenzilumab compared to the control group Median time to resolution of acute respiratory distress syndrome (ARDS) reduced to one day for patients treated with lenzilumab versus eight days in control group Lenzilumab patients discharged from the hospital in less than half the time compared with control group BURLINGAME, Cali

Cybin Corp. (the “Company or “Cybin”), a life sciences company advancing psychedelic pharmaceuticals, is pleased to announce that Mr. Doug Drysdale has been appointed as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200901005388/en/ Mr. Doug Drysdale, CEO of Cybin Corp. (Photo: Business Wire) Doug has more than 30 years of experienc

Mevion Medical Systems and Proton International announced today that they have signed a two-system contract to bring Mevion’s compact proton therapy solution to new centers in locations to be announced in South Texas and the Southeast United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200901005396/en/ The MEVION S250i Proton Therapy System

Various Atara Posters Being Presented at ACTRIMS-ECTRIMS Further Elucidate the Role of EBV in MS Company to Host Live Conference Call and Webcast to Review MS Data Presentation on Friday, September 11, 2020 at 8:30 a.m. ET/5:30 p.m. CEST SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for pa

Bicycle Therapeutics Announces First Patient Dosed in Oxurion’s Phase II Trial Using a Novel Bicycle ® -based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema CAMBRIDGE, England & BOSTON--( BUSINESS WIRE )-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that the first

80% reduction in relative risk of invasive mechanical ventilation and/or death in patients treated with lenzilumab compared to the control group Median time to resolution of acute respiratory distress syndrome (ARDS) reduced to one day for patients treated with lenzilumab versus eight days in control group Lenzilumab patients discharged from the hospital in less than half the time compared with control group BURLINGAME, CA / ACCESSWIRE / September 1, 2020 / Humanigen, Inc. , (OTCQB:HGEN)

SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced today that the company will be participating in the upcoming Morgan Stanley 18 th Annual Global Healthcare Conference and the 2020 Cantor Global Healthcare Conference. For the Morgan Stanley Global Healthcare Conference, SI-BONE’s management is scheduled for a Fireside Chat on Tuesday, Septemb